A Healthy Volunteer Safety Study of Pyronaridine Tetraphosphate Taken in Combination With Piperaquine Tetraphosphate

PHASE1CompletedINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

February 14, 2022

Primary Completion Date

May 31, 2022

Study Completion Date

May 31, 2022

Conditions
Healthy
Interventions
DRUG

Pyronaridine Tetraphosphate

A total of 24 participants will be dosed with pyronaridine tetraphosphate, sixteen participants will be additionally be dosed with piperaquine tetraphosphate, eight patients will additionally be dosed with placebo.

DRUG

Piperaquine tetraphosphate

A total of 24 participants will be dosed with piperaquine tetraphosphate, sixteen participants will be additionally be dosed with pyronaridine tetraphosphate, eight patients will additionally be dosed with placebo.

DRUG

Placebo

Placebo tablets will be administered in combination with pyronaridine tetraphosphate (8 patients), OR, in combination with piperaquine tetraphosphate (8 patients), OR, only matched placebo tablets will be administered (8 patients)

Trial Locations (1)

SE1 1YR

Richmond Pharmacology Ltd, London

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Richmond Pharmacology Limited

INDUSTRY

collaborator

PharmaKinetic Ltd

INDUSTRY

lead

Medicines for Malaria Venture

OTHER